Poteligeo

— THERAPEUTIC CATEGORIES —
  • Leukemias, lymphomas, and other hematologic cancers

Poteligeo Generic Name & Formulations

General Description

Mogamulizumab-kpkc 20mg/5mL; soln for IV infusion; preservative-free.

Pharmacological Class

CCR4-directed monoclonal antibody.

How Supplied

Single-dose vial—1

Manufacturer

Generic Availability

NO

Poteligeo Indications

Indications

In adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.

Poteligeo Dosage and Administration

Adult

Premedicate with diphenhydramine and acetaminophen for the 1st infusion. Infuse IV over ≥60mins. 1mg/kg on Days 1, 8, 15, and 22 of the first 28-day cycle, then on Days 1 and 15 of each subsequent cycle until disease progression or unacceptable toxicity. Dose modifications for toxicity: see full labeling.

Children

Not established.

Poteligeo Contraindications

Not Applicable

Poteligeo Boxed Warnings

Not Applicable

Poteligeo Warnings/Precautions

Warnings/Precautions

Monitor for skin rash; permanently discontinue if SJS/TEN or life-threatening reaction (Grade 4) occurs. Monitor for infusion reactions; interrupt for any grade reaction and treat promptly; permanently discontinue for life-threatening reaction (Grade 4). Monitor for infection; treat promptly. History of autoimmune disease. Interrupt or permanently discontinue as appropriate if immune-mediated adverse reactions suspected. Complications of allogeneic HSCT after Poteligeo (including severe acute GVHD, steroid-refractory GVHD, transplant-related death); monitor closely. Verify pregnancy status prior to initiation. Advise females of reproductive potential to use effective contraception during and for 3 months after the last dose. Pregnancy: not recommended. Nursing mothers.

Poteligeo Pharmacokinetics

See Literature

Poteligeo Interactions

Not Applicable

Poteligeo Adverse Reactions

Adverse Reactions

Rash, infusion related reactions, fatigue, diarrhea, musculoskeletal pain, upper RTI, skin infection, pyrexia, nausea, edema, thrombocytopenia, headache, constipation, mucositis, anemia, cough, hypertension.

Poteligeo Clinical Trials

See Literature

Poteligeo Note

Not Applicable

Poteligeo Patient Counseling

See Literature